[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Princess Nourah Bint Abdulrahman University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100628672","effect-of-prebiotics-in-saudi-adults-with-type-2-diabetes-100628672",false,"NCT07464691","Effect of Prebiotics in Saudi Adults With Type 2 Diabetes","Effect of Prebiotics in Saudi Adults With Type 2 Diabetes: Randomized Control Trail","Inclusion Criteria:\n\n* Saudi, both males and females.\n* Aged between 45-60 years old\n* BMI between 25 - 30 kg\u002Fm2\n* No antibiotic use for the last six months\n\nCases:\n\n* Type 2 diabetes.\n* Duration of diabetes ≥ 5 years\n* HbA1c ≥ 6.5-8.0\n\nControls: (subjects with normal OGTT results)\n\n* Fasting plasma glucose (FPG) \\\u003C 100 mg\u002Fdl (5.6mmol\u002Fl)\n* A1C less than 5.7%\n* 2-hour post-load glucose \\\u003C 140 mg\u002Fdl (7.8 mmol\u002Fl)\n\nExclusion Criteria:\n\n1. Patients with Type 1 diabetes.\n2. Pregnant \\& breastfeeding females.\n3. Any serious disease such as renal or hepatic disease, thyroid functions, coeliac disease, or the presence of gastroparesis.\n4. Use of weight-loss treatments within 3 months before inclusion\n5. Diabetic patients on acarbose, metformin (\\> 1 g\u002Fday), and GLP-1 medications.\n6. Use of antibiotic drugs for the last 3 months of treatments that influence gut microbiota composition.\n7. Bypass surgery, Laparoscopic Sleeve Gastrectomy (LSG), or colon restriction.\n8. Chronic gastrointestinal disorder (except irritable bowel syndrome).\n9. Patients with a history or symptoms of obstruction or Inflammatory bowel disease\n10. Atypical diets (such as vegetarians, vegans, and heavy consumption of dietary supplements).\n11. Use of pre\u002Fprobiotics or fiber supplements within 3 months before inclusion.\n12. Any drug that can interfere with food absorption or gut flora, such as chronic consumption of loperamide, cholestyramine, antacids, H2-receptor blockers, proton pump inhibitors, fibrates, corticosteroids, or sex steroids, omega-3 unsaturated fatty acids acid, or anti-inflammatory drugs.\n13. Autonomic neuropathy\n14. Any immune-compromised disease.\n15. Daily alcohol consumption \\> 30 g.\n16. Involvement in another clinical trial in the past 6 months.\n17. Any legal incompetence or mental inability to provide consent.",true,"ALL","45 Years","60 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study will explore how a natural food ingredient called oligofructose affects blood glucose levels, lipid profiles, inflammation biomarkers, and gut bacteria in Saudi adults with type 2 diabetes. Oligofructose is a type of dietary fiber found in foods such as onions, garlic, and bananas. It is known to help the growth of \"good\" bacteria in the intestine, which may improve digestion and metabolism.\n\nA total of 100 adults (50 with type 2 diabetes and 50 without diabetes) will take part in this research. Participants will be randomly assigned to receive either oligofructose or a placebo twice daily for 12 weeks. Blood tests will be done at the beginning and at weeks 4, 8, and 12 to check changes in blood glucose, lipid profiles, and inflammation.\n\nThe goal of this study is to find out whether adding oligofructose to the diet can help people with diabetes improve their blood glucose control, reduce inflammation, and support a healthier balance of gut bacteria.",[28,29,30,31,32],"Type 2 Diabetes","Metabolic Health","Inflammation","Gut Microbiome","Obesity",[34,35,31,36],"Prebiotics","Dietary supplement","Oligofructose","NOT_YET_RECRUITING","2026-03-09",{"date":40,"type":41},"2026-03-11","ACTUAL",{"date":43,"type":22},"2026-09-13",{"date":45,"type":22},"2027-12-31",{"name":47,"class":48},"Princess Nourah Bint Abdulrahman University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":49},"100605957","effects-of-wet-cupping-on-polycystic-ovary-syndrome-patients-100605957","NCT07169292","Effects of Wet-Cupping on Polycystic Ovary Syndrome Patients","Effects of Wet-Cupping on Polycystic Ovary Syndrome Patients: A Randomized Controlled Trial","Inclusion Criteria\n\n* Female participants.\n* Aged 20 to 40 years.\n* Diagnosed with Polycystic Ovary Syndrome (PCOS) according to the Rotterdam criteria.\n* Willing to participate in the study and provide informed consent.\n* Not using any of the following in the last month: (Hormonal medications for menstruation, Herbal menstrual remedies or Metformin).\n\nExclusion Criteria\n\n* Known diagnosis of uncontrolled thyroid dysfunction.\n* Diagnosis of diabetes mellitus.\n* Elevated FSH levels above 20 mIU\u002FmL.\n* Hyperprolactinemia with serum levels above 1000 mIU\u002FL.\n* Pregnant or lactating women.\n* Known coagulation disorders.\n* Anemia with hemoglobin levels less than 10 g\u002FdL.\n* History of undergoing dry cupping, wet cupping, or acupuncture in the past 6 months.\n* History of surgical removal of both ovaries or the uterus.\n* Other causes of hyperandrogenism, including:\n* Late-onset non-classic 21-hydroxylase deficiency (excluded clinically; lab investigation if clinically indicated).\n* Ovarian androgen-secreting tumors.\n* Use of anabolic or androgenic drugs.\n* Cushing's syndrome.\n* Hypothalamic or pituitary disorders causing amenorrhea.\n* Primary ovarian insufficiency.","FEMALE","20 Years","40 Years",{"count":61,"type":22},60,[25],"The goal of this clinical trial is to evaluate whether wet cupping therapy (Hijama) can improve reproductive and metabolic outcomes in women diagnosed with Polycystic Ovary Syndrome (PCOS). This study will be conducted among female participants aged 20-40 years who have been diagnosed with PCOS according to the Rotterdam criteria.\n\nThe main questions it aims to answer are:\n\nCan wet cupping therapy regulate menstrual cycles in women with PCOS?\n\nCan it increase the pregnancy rate in married participants with PCOS-related infertility?\n\nResearchers will compare outcomes between a wet cupping group and a control group to determine whether Hijama has significant effects on reproductive, hormonal, and metabolic markers.\n\nParticipants will:\n\nUndergo screening and eligibility evaluation using a checklist\n\nBe randomized into either the wet cupping (intervention) or control group\n\nReceive lifestyle counseling (diet and physical activity)\n\nFor the intervention group:\n\nReceive one Hijama session performed by a certified practitioner\n\nUndergo follow-up at 4 and 12 weeks for clinical, hormonal, and ultrasound assessments\n\nFor all participants:\n\nComplete laboratory tests, ultrasound scans, and questionnaires on PCOS symptoms and quality of life\n\nReport any side effects during and after the study period",[65],"Polycystic Ovarian Syndrome (PCOS)","2025-09-05",{"date":68,"type":41},"2025-09-11",{"date":70,"type":22},"2026-01-01",{"date":72,"type":22},"2026-12-31",{"name":47,"class":48},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":99,"locationsCount":49},"100487701","lifestyle-management-app-for-adults-with-diabetes-type-100487701","NCT05630508","Lifestyle Management App for Adults With Diabetes Type","mHealth Lifestyle Management Program (LIVEN) For Adults With Diabetes Type 2: A Feasibility Study","LIVEN","Inclusion Criteria:\n\n* Adults, aged 18 years or older\n* Arabic speakers\n* Capable of utilizing smartphones\n* Diagnosed with T2DM\n* Poor glycemic control: A1c \\> 7.5%\n\nExclusion Criteria:\n\n* Individuals using insulin injection\n* Individuals suffering from disorders that might affect intervention (e.g. amputation, enucleation of the eye, or end-stage kidney disease)\n* Women who are pregnant or breastfeeding\n* Individuals diagnosed with other types of diabetes (such as type I or MODY)","18 Years",{"count":84,"type":22},90,[25],"This study will evaluate whether the 12-week health coaching mobile application (LIVEN) will succeed in enhancing lifestyle behaviors in adults with Type 2 Diabetes compared to typical treatment. The mobile application's viability will be assessed in 2 parts; the first part is testing easiness and friendliness of using Liven by the patient and health coach. The second part is evaluating the suitability of Liven education material for the patients and whether the coaching program results in enhancing lifestyle behaviors and blood sugar levels. the investigators hypothesize that the 12-week online lifestyle-coaching program will be viable, and a full-scale study can proceed.",[88],"Diabetes Mellitus, Type 2",[90,91],"Type 2 diabetes management","Mhealth lifestyle management program","RECRUITING","2025-06-23",{"date":95,"type":41},"2025-06-26",{"date":97,"type":41},"2022-10-01",{"date":72,"type":22},{"name":47,"class":48},""]